You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 11, 2025

Esmolol hydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for esmolol hydrochloride and what is the scope of freedom to operate?

Esmolol hydrochloride is the generic ingredient in six branded drugs marketed by Baxter Hlthcare, Am Regent, Amneal, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Hq Spclt Pharma, Mylan Institutional, Mylan Labs Ltd, and Sagent Pharms Inc, and is included in thirteen NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Esmolol hydrochloride has seven patent family members in seven countries.

There are five drug master file entries for esmolol hydrochloride. Twelve suppliers are listed for this compound.

Summary for esmolol hydrochloride
Recent Clinical Trials for esmolol hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Pakistan Institute of Medical SciencesPhase 4
Muhammad Haroon AnwarPhase 4
Consorcio Centro de Investigación Biomédica en Red (CIBER)Phase 3

See all esmolol hydrochloride clinical trials

Pharmacology for esmolol hydrochloride
Anatomical Therapeutic Chemical (ATC) Classes for esmolol hydrochloride
Paragraph IV (Patent) Challenges for ESMOLOL HYDROCHLORIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
BREVIBLOC IN PLASTIC CONTAINER Injection esmolol hydrochloride 10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bags 019386 1 2014-01-31

US Patents and Regulatory Information for esmolol hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Baxter Hlthcare BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER esmolol hydrochloride INJECTABLE;INJECTION 019386-005 Jan 27, 2003 AP RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Eugia Pharma ESMOLOL HYDROCHLORIDE esmolol hydrochloride INJECTABLE;INJECTION 216244-002 Mar 21, 2022 AP RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Eugia Pharma ESMOLOL HYDROCHLORIDE esmolol hydrochloride INJECTABLE;INJECTION 216244-001 Mar 21, 2022 AP RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for esmolol hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Baxter Hlthcare BREVIBLOC IN PLASTIC CONTAINER esmolol hydrochloride INJECTABLE;INJECTION 019386-004 Feb 16, 2001 6,310,094*PED ⤷  Try for Free
Baxter Hlthcare BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER esmolol hydrochloride INJECTABLE;INJECTION 019386-005 Jan 27, 2003 6,310,094*PED ⤷  Try for Free
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-007 May 28, 2003 6,528,540*PED ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for esmolol hydrochloride

Country Patent Number Title Estimated Expiration
European Patent Office 2948379 COMPOSITION PHARMACEUTIQUE DE COSOLVANTS PRÊTE À L'UTILISATION DANS DES RÉCIPIENTS DE MATIÈRE PLASTIQUE FLEXIBLES MODIFIÉS (READY-TO-USE CO-SOLVENTS PHARMACEUTICAL COMPOSITION IN MODIFIED FLEXIBLE PLASTIC CONTAINER) ⤷  Try for Free
China 105263809 Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container ⤷  Try for Free
Australia 2014228155 Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container ⤷  Try for Free
>Country >Patent Number >Title >Estimated Expiration

Esmolol Hydrochloride Market Dynamics and Financial Trajectory

Market Overview

Esmolol hydrochloride, a short-acting beta-blocker, is widely used for managing various cardiovascular conditions, including supraventricular tachycardia, noncompensatory sinus tachycardia, and perioperative hypertension. The global market for esmolol hydrochloride is poised for significant growth, driven by several key factors.

Global Market Size and Growth Rate

The global esmolol hydrochloride market is estimated to expand at a compound annual growth rate (CAGR) of 3.5% to 4.8% from 2024 to 2030/2031. By 2030, the market size is projected to reach approximately $487.2 million[3][2].

Regional Market Dynamics

North America

North America currently dominates the esmolol hydrochloride market, driven by the increasing incidence of heart diseases and the presence of well-established healthcare infrastructure. The region is expected to grow at a CAGR of 2.2% from 2024 to 2031, with the United States, Canada, and Mexico contributing significantly to this growth[1][2].

Asia-Pacific

The Asia-Pacific region is anticipated to witness substantial growth, driven by rising healthcare expenditure, growing awareness of cardiovascular health, and an increase in lifestyle-related health issues. This region holds the majority market share and is expected to grow at a CAGR of 6.0% from 2024 to 2031[1][3].

Europe

Europe is another significant market for esmolol hydrochloride, with a CAGR of 2.5% from 2024 to 2031. The region's growth is fueled by advancements in critical care and anesthesiology, as well as the increasing geriatric population[1][2].

Latin America and Middle East & Africa

Latin America and the Middle East & Africa are also growing markets, albeit at a slower pace. Latin America is expected to grow at a CAGR of 3.4%, while the Middle East & Africa will grow at a CAGR of 3.7% from 2024 to 2031[1].

Key Drivers of Market Growth

Rising Prevalence of Cardiovascular Diseases

The increasing prevalence of cardiovascular diseases globally is a major driver of the esmolol hydrochloride market. As the population ages and lifestyle-related health issues rise, the demand for effective cardiovascular treatments is escalating[2][3].

Growing Number of Surgical Procedures

The rise in surgical procedures, particularly in perioperative settings, is boosting the demand for esmolol hydrochloride. Its rapid onset and short half-life make it ideal for acute heart rate control during surgeries[1][3].

Advancements in Healthcare Infrastructure

Heightened investments in healthcare infrastructure, especially in emerging economies, are enhancing access to advanced treatment options, including esmolol hydrochloride. Government initiatives to improve healthcare access and infrastructure further support market growth[3].

Regulatory Approvals and Expanded Indications

Regulatory approvals for expanded indications of esmolol hydrochloride have significantly contributed to market growth. The drug is now approved for broader applications, including perioperative hypertension and arrhythmia management in intensive care settings[3].

Competitive Landscape

The esmolol hydrochloride market is highly competitive, with key players such as Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., and Aurobindo Pharma Ltd. These companies are adopting strategies like mergers and acquisitions, product launches, and geographical expansion to strengthen their market presence. Innovations in formulations and delivery systems, as well as collaborations with research institutions, are also driving market expansion[2].

End-Use Segmentation

Hospitals

Hospitals are the largest consumers of esmolol hydrochloride, using the drug extensively for managing tachycardia and high blood pressure during surgeries. The growing focus on patient safety and effective intraoperative control is boosting demand in hospital settings[1].

Clinics and Research Institutes

Clinics and research institutes also play a significant role in the market, particularly in the development and testing of new formulations and applications of esmolol hydrochloride[3].

Financial Trajectory

The financial trajectory of the esmolol hydrochloride market is positive, with steady growth anticipated over the forecast period. Here are some key financial highlights:

  • Global Market Size: Expected to reach $487.2 million by 2030[3].
  • CAGR: Ranging from 3.5% to 4.8% from 2024 to 2030/2031[2][3].
  • Regional Growth: North America, Asia-Pacific, and Europe are expected to contribute significantly to the market's financial growth[1][2].

Challenges and Opportunities

Generic Competition

The presence of generic alternatives is a significant challenge for branded manufacturers, as it drives down prices and affects profitability. However, this competition also benefits healthcare systems and patients by making treatment options more accessible[1].

Innovation and Strategic Partnerships

Pharmaceutical companies are focusing on innovation and strategic partnerships to develop novel formulations and improve patient compliance. This approach is expected to drive product development and market expansion[2].

Key Takeaways

  • The global esmolol hydrochloride market is driven by the rising prevalence of cardiovascular diseases and the growing demand for effective treatments.
  • North America and Asia-Pacific are key regions driving market growth.
  • Regulatory approvals for expanded indications and advancements in healthcare infrastructure are significant growth drivers.
  • Hospitals are the largest consumers of esmolol hydrochloride.
  • The market is expected to grow steadily, with a projected CAGR of 3.5% to 4.8% from 2024 to 2030/2031.

FAQs

  1. What is the projected CAGR of the global esmolol hydrochloride market from 2024 to 2030/2031?

    • The projected CAGR ranges from 3.5% to 4.8% from 2024 to 2030/2031[2][3].
  2. Which region dominates the esmolol hydrochloride market?

    • North America currently dominates the market, but the Asia-Pacific region is expected to witness substantial growth[1][2].
  3. What are the key drivers of the esmolol hydrochloride market?

    • The rising prevalence of cardiovascular diseases, growing number of surgical procedures, and advancements in healthcare infrastructure are key drivers[2][3].
  4. Who are the major players in the esmolol hydrochloride market?

    • Key players include Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., and Aurobindo Pharma Ltd.[2].
  5. What is the expected global market size of esmolol hydrochloride by 2030?

    • The global market size is estimated to reach approximately $487.2 million by 2030[3].

Cited Sources

  1. Cognitive Market Research: Esmolol Hydrochloride Market Report 2024 (Global Edition)[1].
  2. MarkWide Research: Esmolol Hydrochloride Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030[2].
  3. IndustryARC: Esmolol Hydrochloride Market – Forecast(2024 - 2030)[3].

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.